Key points are not available for this paper at this time.
FDA cleared a TMS treatment protocol with fMRI-guided individualized targeting for major depressive disorder. This protocol was based on 3T scanner. However, 1.5 T MRI is more widely available in hospitals. We comprehensively tested the reliability and sensitivity of fMRI metrics related to TMS treatment on 1.5T and 3T scanners. In general, the sensitivity of 3T is larger than 1.5T. However, the reproducibility of peak FC location and the activation location, the reliability of RS-fMRI local metrics, are similar for 1.5T and 3T. In conclusion, 1.5 fMRI meets the needs for guiding individualized precise rTMS treatment.
Ge et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: